TESSERA THERAPEUTICS STOCKS CODE

McFadyen held executive and senior leadership positions at LifeMine Therapeutics and Moderna, Inc., respectively. Iain McFadyen serves as Chief Data Officer to help advance TesseraвЂ™s goal of developing potentially curative medicines across multiple therapeutic areas. I look forward to working with the incredible team to advance our Gene Writing platform and to develop win-state medicines that can transform the lives of patients.'Дr. 'Our Gene Writer tools can make single base pair changes, insertions and deletions, and write entire genes, each with meaningful advantages over current tools, and without reliance upon viral vectors. 'After working in the field of genetic medicine for more than 20 years, I was inspired by the capabilities and performance of TesseraвЂ™s Gene Writer candidates and their potential to fundamentally reshape the field of genetic medicine,' said Dr. Holmes has authored more than 60 publications in the field of genome editing and gene regulation and he is listed as an inventor on more than 40 issued and pending U.S. in Molecular Biology from the University of California, San Diego. in Molecular and Cell Biology from the University of California, Berkeley. He was also responsible for the research efforts to develop the SB-525 human factor 8 protein (hFVIII) cDNA program, which achieved the highest ever reported level of hFVIII in animal studies and is currently being evaluated in a Phase III study for hemophilia A.Дr.

Holmes led the efforts that resulted in the first ever clinical candidate of a genome editing-based therapy and has extensive experience in the genome editing of T-cells, hematopoietic stem cells, and hepatocytes. Holmes was the Chief Scientific Officer of Ambys Medicines, and he also held various leadership positions at Sangamo Therapeutics, Inc., including Senior Vice President and Chief Technology Officer.Дr. He has an accomplished track record of translating genome engineering technologies to product candidates as evidenced by leading ten therapeutic programs across ex vivo and in vivo therapies. Holmes has more than 20 years of experience working on the development and clinical translation of genome editing- and gene therapy-based approaches. Michael Holmes has joined Tessera Therapeutics as its Chief Scientific Officer to lead the development of novel technologies and transformative therapies. Michael Holmes, Ph.D., Chief Scientific OfficerДr. WeвЂ™re thrilled that our research will be led by Mike Holmes, whose previous roles included spearheading development of the industryвЂ™s first gene editing platform and therapeutic candidates.' 'To realize this goal, weвЂ™re building the fieldвЂ™s top team across all levels and functions of our organization. 'We set out to revolutionize the field of genetic medicine by pioneering Gene Writing technology that can unlock the therapeutic potential of engineering DNA and address the short-comings of todayвЂ™s gene therapy and gene editing approaches,' said Dr.

'Their leadership, experiences, and mindsets will be critical in helping to realize our aspirations in genetic medicine, attract and maintain the best talent, and develop our pipeline of Gene Writer candidates to cure and prevent severe diseases.' Geoffrey von Maltzahn, CEO and Co-Founder of Tessera and General Partner, Flagship Pioneering.

TESSERA THERAPEUTICS STOCKS CODE

'Michael, Iain, and Bec are invaluable additions to our Tessera team and our mission to cure disease by writing in the code of life,' said Dr. In addition to the three executive appointments, Rebecca Wais, Ph.D., JD, Vice President, Intellectual Property and Legal Affairs, and Ian OвЂ™Reilly, Vice President, Head of GMP Quality, recently joined the Tessera team to bolster the companyвЂ™s internal legal and manufacturing capabilities. Jacob Rubens, Ph.D., Co-Founder of Tessera and Senior Principal, Flagship Pioneering, has transitioned from TesseraвЂ™s Chief Scientific Officer to Chief Innovation Officer.

as Chief Data Officer, and Becky Lillie as Chief Human Resources OfficerД¬AMBRIDGE, Mass., December 08, 2021-( BUSINESS WIRE)-Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicine known as Gene Writingв„ў technology, today announced the expansion of its executive leadership team with appointments of Michael Holmes, Ph.D., Chief Scientific Officer, Iain McFadyen, Ph.D., Chief Data Officer, and Becky Lillie, Chief Human Resources Officer. as Chief Scientific Officer, Iain McFadyen, Ph.D. Company expands roster of industry experts with the additions of Michael Holmes, Ph.D.

Tessera therapeutics stocks